Qiagen (NYSE:QGEN) Shares Bought by Mackenzie Financial Corp

Mackenzie Financial Corp raised its position in Qiagen (NYSE:QGEN) by 8.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 424,685 shares of the company’s stock after buying an additional 31,758 shares during the quarter. Mackenzie Financial Corp’s holdings in Qiagen were worth $17,539,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Qiagen by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock valued at $382,856,000 after buying an additional 83,371 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Qiagen by 0.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock worth $151,526,000 after purchasing an additional 26,078 shares in the last quarter. Optiver Holding B.V. boosted its position in shares of Qiagen by 1,211.4% during the 4th quarter. Optiver Holding B.V. now owns 47,212 shares of the company’s stock worth $2,050,000 after purchasing an additional 43,612 shares in the last quarter. Sei Investments Co. boosted its position in shares of Qiagen by 49.0% during the 4th quarter. Sei Investments Co. now owns 1,196,476 shares of the company’s stock worth $51,963,000 after purchasing an additional 393,553 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Qiagen by 124.4% during the 1st quarter. US Bancorp DE now owns 75,529 shares of the company’s stock worth $3,247,000 after purchasing an additional 41,868 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on QGEN. Robert W. Baird boosted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Finally, Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research note on Thursday, June 27th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

Qiagen Trading Up 0.5 %

Shares of QGEN stock opened at $45.24 on Monday. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.44. The firm’s 50-day simple moving average is $45.20 and its 200-day simple moving average is $43.48. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. The firm has a market cap of $10.32 billion, a P/E ratio of 30.34, a PEG ratio of 3.20 and a beta of 0.39.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. During the same quarter last year, the firm posted $0.53 earnings per share. Qiagen’s revenue for the quarter was down .2% compared to the same quarter last year. As a group, equities analysts forecast that Qiagen will post 2.15 EPS for the current year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.